Europe Oligonucleotide Synthesis Market

The Europe Oligonucleotide Synthesis market is expected to reach US$ $ 1,270.95 Mn in 2027 from US$ 518.02 Mn in 2018. The market is estimated to grow with a CAGR of 13.7% from 2019-2027.

The growth of the market is driven by the factors such as, research and academic universities are collaborating with commercial market players to develop techniques and simplify the method of artificial DNA synthesis as well as rise in the number of market players and their focus in the oligonucleotide synthesis are likely to boost the growth of the oligonucleotide synthesis in the region during the forecast period.

Synthetic DNA is widely used in biology. Oligonucleotides are used in many biological and forensic applications as sequence-specific binding agents can help in identifying presence of a specific target DNA sequence. Synthetic oligonucleotides are short stretches of single stranded DNA fragments assembled by chemical synthesis. Due to the simultaneous developments of methods for the rapid and efficient synthesis of oligonucleotides and the advent of molecular biology techniques.

Oligonucleotides have many applications in research, diseases diagnosis, therapeutics, forensic, drug discovery, agriculture and many more. Synthetic oligonucleotides are widely used in the diagnosis of human genetic diseases. In addition, the players operating in the UK oligonucleotide synthesis market have been obtaining funds in order to enhance their product offering. For instance, in March, 2019, UK based privately held biotech company, Procarta Biosystems received a fund of US$ 1.69 Mn (€1.5 m) from the Novo Holdings REPAIR Impact Fund in order to enable the development of novel therapies to combat antimicrobial resistance (AMR).

Researchers are also using oligonucleotides to produce more efficient, greener chemical synthesis. By assembling oligonucleotides together into longer fragments that encode synthetic genes, bacteria or yeast cells can be instructed to produce specific enzymes (a type of protein).

Oligonucleotides also has wide potential for treating various medical conditions. They enable the development of therapeutics as the malfunctioning genes can be targeted, manipulated, silenced and/or modulated. For instance, Ionis Pharmaceuticals has dedicated its existence to oligonucleotide therapeutic development, particularly antisense oligonucleotide (ASO) therapeutics. Thus, the promising potential of synthesized oligonucleotides in various fields drives the market growth.

Spain is expected to lead the market in the Europe region owing to growing number of partnerships and collaborations among private players, rising investments and funding dedicated to the biotechnology companies as well as academic and research institutes for gene synthesis based end products. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the Europe region during the forecast period.

Italy Oligonucleotide Synthesis Market Revenue and Forecasts to 2027 (US$ Mn)

Europe Oligonucleotide Synthesis Strategic Insights

Strategic insights for the Europe Oligonucleotide Synthesis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Oligonucleotide Synthesis Report Scope

Europe Oligonucleotide Synthesis Regional Insights

The geographic scope of the Europe Oligonucleotide Synthesis refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

EUROPE OLIGONUCLEOTIDE SYNTHESIS – MARKET SEGMENTATION

By Product

• Synthesized Oligonucleotides
  • Primers
  • Probes
  • Large-Scale Synthesis
  • Others
• Reagents
  • Equipment

By Application

• Research
• Diagnostics
• Therapeutics

By

End User

• Academic Research Institutes
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Other End Users

By Geography

• Europe

  • US
  • Canada
  • Mexico

Company Profiles

• Thermo Fisher Scientific Inc.
• GenScript
• Molecular Assemblies
• Twist Biosciences
• Evonetix
• DNA Script
• Nuclera Nucleics
• Camena Bioscience
• Synthomics
• Ansa Biotechnologies